A combination of bioflavonoid, oral thrombolytic and anticoagulant in the treatment of thrombophlebitis of varicose veins in outpatient surgical practice

Е. П. Кривощеков, A. V. Poseryaev, M. Khoroshilov, V. E. Romanov, B. M. Rakhimov, А. В. Казанцев, S. Zh. Kirgizbaev

2024

Full text Open access: Gold Metadata (CSL-JSON)
DOI 10.21518/akh2024-025
Data confidence 85 high
How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

Introduction. Comparability of the outcomes of treatment of patients with thrombophlebitis of varicose veins using surgical intervention and medical therapy, a wide range of drugs have become the basis for conducting this study.Aim. To evaluate the effectiveness of the use of micronized purified flavonoid fraction in comparison with the isolated use of diosmin in patients with superficial varicothrombophlebitis in outpatient surgical practice.Materials and methods. From 2021 to 2022, a prospective study of the treatment results of 82 patients (from 42 to 68 years old, average age: 54.3 ± 12.34 years) with a diagnosis of superficial vein thrombophlebitis was conducted. To relieve inflammation as soon as possible and accelerate recanalization, a direct oral thrombolytic was prescribed. The patients were divided into two groups. The main group (44 patients) took a drug consisting of diosmin 900 mg (90%) and flavonoids in terms of hesperidin 100 mg (10%). In the comparison group (38 people), unmicronized diosmin was taken at a dosage of 600 mg.Results and discussion. Thrombophlebitis of superficial veins was more often localized in the basin of the great saphenous vein (47 patients (57.3%)). On the 30th day after the start of treatment, there was no progression of the thrombotic process. In the main and control groups, the symptoms of thrombophlebitis (a feeling of tightness under the skin and local soreness in the area of varicose veins) were eliminated in 34 (77.3%) of the main group and 22 (57.9%) patients of the comparison group. There was a decrease in the signs of chronic venous insufficiency from 73.7 to 36.4%, as well as a statistically large proportion of patients with complete or partial recanalization (70.5 vs 44.5% in the control group).Conclusion. The results of the study show that the micronized purified flavonoid fraction has advantages over non-micronized diosmin in reducing the severity of symptoms, significantly reducing the signs of chronic venous insufficiency and improving quality.